There are currently three approved vaccines against the H5N1 avian influenza virus. However, they present challenges for large-scale virus cultivation in case of an outbreak and rapid update of vaccine strains to keep pace with the virus’s evolution. Messenger RNA (mRNA) vaccine platforms may offer a promising alternative to traditional vaccine methods to face H5N1 threats.

Deciphera Pharmaceuticals LLC has patented new serine/threonine-protein kinase B-raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) inhibitors reported to be useful for the treatment of cancer.

Humanwell Healthcare (Group) Co. Ltd. has developed new heterocyclic compounds acting as angiotensin AT2 receptor antagonists reported to be useful for the treatment of neuropathy and neuropathic pain.

Quanta Therapeutics Inc. has identified new pyrimidine-based GTPase KRAS G12D and G12V mutant inhibitors potentially useful for the treatment of cancer.

Astrazeneca AB patents describe new proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety reported to be useful for the treatment of cancer.

Researchers from Northeastern University and the University of Georgia have synthesized new tetrahydroacridinone analogues.

The standard treatment for non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guérin (BCG). However, despite it being effective, many patients experience recurrences, and others become unresponsive. The activation of the intracellular transmembrane receptor stimulator of interferon genes (STING) has shown antitumoral effects in murine cancer models.